Why the study?
Does low molecular weight heparin improve lipid metabolism compared to unfractionated heparin in patients on chronic hemodialysis?
Does low molecular weight heparin improve lipid metabolism compared to unfractionated heparin in patients on chronic hemodialysis?
In chronic hemodialysis patients, LMWH does not provide a beneficial effect on lipid metabolism compared to UFH, challenging previous assumptions.
Answers are grounded in this paper and cite their sources.
LMWH was associated with lower HDL than UFH in hemodialysis; hypothesis-generating and requires prospective confirmation before any practice implications.
Recent studies have indicated controversial effects of low molecular weight heparin (LMWH) on lipid metabolism in patients on chronic hemodialysis as compared to unfractionated heparin (UFH). We therefore conducted a cross-sectional multicentre study comparing 153 patients treated with LMWH and 153 patients with UFH, matched for sex, age and diabetes mellitus. Both groups have been treated with LMWH or UFH for six months or longer (14.9 vs. 23.4 months). We observed no differences between the UFH and LMWH treatment groups for total cholesterol, LDL cholesterol, triglycerides, apoB, apoA-IV or Lp(a). The only significant differences were seen for HDL cholesterol and the corresponding apolipoprotein apoA-I, which were significantly higher in the UFH group (HDL cholesterol: 0.97 +/- 0.35 mM/l vs. 0.87 +/- 0.37 mM/l, p < 0.05; apoA-I 1.23 +/- 0.27 g/l vs. 1.15 +/- 0.27 g/l, p < 0.05). We conclude that the results of studies investigating the influence of LMWH on lipid metabolism are as heterogeneous as the substances themselves. This challenges the beneficial influence supposedly had by LMWH preparations on lipid metabolism.
No takes yet. Share an insight, caveat, or question.
Kronenberg et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: